IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Clinical Trials
12
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2010
Active, not recruiting
2
16.7%
Completed
1
8.3%
No Longer Available
1
8.3%
Terminated
8
66.7%
No approval data available
- Cargo Therapeutics agreed to be acquired by Concentra Biosciences for approximately $202 million upfront after halting development of its lead CAR-T therapy firicabtagene autoleucel due to poor durability results. - The company's Phase II trial showed firi-cel achieved a 77% response rate but only 18% durability at three months, leading to rapid patient relapse and termination of the mid-stage study in January. - Concentra, backed by Tang Capital Partners, continues its acquisition strategy targeting distressed biotechs, having completed five buyouts in 2024 including Elevation Oncology and Kronos Bio. - The deal provides Cargo shareholders with 100% of net cash above $217.5 million at closing plus 80% of proceeds from asset sales within two years, effectively winding down the company that raised $200 million in 2023.
- IGM Biosciences has stopped the development of imvotamab and IGM-2644 after Phase 1b trials showed insufficient B cell depletion in rheumatoid arthritis and lupus patients. - The company is reducing its workforce by 73% to preserve cash and is exploring strategic alternatives, including a potential sale or merger. - Interim data indicated that imvotamab, a CD20 x CD3 bispecific antibody, did not meet the company's criteria for success in B cell depletion. - The decision marks a strategic shift for IGM, which initially focused on cancer therapies before pivoting to autoimmune disease research in 2024.
- Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions. - Several companies, including Intellia Therapeutics and IGM Biosciences, are cutting a significant portion of their workforce to focus on key programs and extend cash runways. - These workforce reductions are often accompanied by discontinuation of certain drug development programs and a shift in strategic focus towards core assets. - The layoffs reflect a broader trend in the industry as companies adapt to evolving market dynamics and prioritize efficiency and long-term sustainability.
- Biopharma job postings declined 16% year-over-year in Q4 2024, with at least 24,000 industry professionals laid off throughout the year, including major cuts at Johnson & Johnson, Bristol Myers Squibb, and Bayer. - Recent positive developments include venture investment reaching $26 billion across 416 rounds in 2024, up from $23.3 billion in 2023, breaking a two-year downward trend in venture capital spending. - Early 2025 has seen significant deal activity at the J.P. Morgan Healthcare Conference, with Eli Lilly, GSK, Gilead, and Johnson & Johnson announcing deals potentially worth over $15 billion combined.
- Candid Therapeutics launched with $370 million in funding to develop bispecific T-cell engagers for autoimmune diseases, acquiring two private biotechs, Vignette Bio and TRC 2004. - The company's pipeline includes two T-cell engagers, targeting BCMA and CD20, which have completed Phase 1 testing in cancer and are slated for autoimmune clinical trials next year. - Candid aims to offer a more commercially viable and convenient alternative to cell therapies for autoimmune diseases, leveraging the potential of bispecific antibodies. - CEO Ken Song believes T-cell engagers represent a transformative approach, citing encouraging case reports and growing industry interest in the field.
